Presentations

Media

Risvodetinib Designated as an Orphan Drug by U.S. FDA.

The role of risvodetinib in the treatment of Parkinson's disease & other CNS diseases

Enrolling treatment-naive patients in Parkinson’s disease clinical trials

Phase II study of risvodetinib in Parkinson's disease

Analysis of the therapeutic potential of c-Abl inhibition in Parkinson's disease & MSA

IKT President & CEO Provides a Brief Overview of the Company

Risvodetinib (IkT-148009) - Addressing Loss of Function in Parkinson's Patients

2023 Virtual R&D Day

rss_feed RSS